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Background: Approximately 10% of women suffer from premature ovarian senescence (POS), ca. 9% as occult
primary ovarian insufficiency (OPOI, also called premature ovarian aging, POA) and ca. 1% as primary ovarian
insufficiency (POI, also called premature ovarian failure, POF). In a large majority of cases POS is currently only
diagnosed at advanced clinical stages when women present with clinical infertility.
Methods: We here, based on published evidence, suggest a new diagnostic paradigm, which is based on identifying
young women at increased risk for POS at much earlier stages.
Results: Risk factors for POS are known from the literature, and can be used to identify a sub-group of young women
at increased risk, who then are followed sequentially with serial assessments of functional ovarian reserve (FOR) until a
diagnosis of POS is either reached or refuted. At approximately 25% prevalence in general U.S. populations
(and somewhat different prevalence rates in more homogenous Asian and African populations), so-called low
(CGGn<26) mutations of the fragile X mental retardation 1 (FMR1) gene, likely, represents the most common
known risk factor, including history-based risk factors from medical, genetic and family histories.
Conclusions: Women so affirmatively diagnosed with POS at relative young ages, then have the opportunity
to reconsider their reproductive planning and/or choose fertility preservation via oocyte or ovarian tissue
cryopreservation at ages when such procedures are clinically much more effective and, therefore, also more
cost-effective. Appropriate validation studies will have to precede widespread utilization of this paradigm.
Keywords: Premature ovarian senescence (POS), Occult primary ovarian insufficiency (OPOI), Fertility
counseling, Reproductive planning, Functional ovarian reserve, Fragile X mental retardation (FMR1) geneBackground
The concept of fertility preservation entered medical
consciousness primarily through the field of oncology,
where increasingly successful chemo- and radiation ther-
apies have improved long-term survival of young cancer
patients but often result in premature ovarian senes-
cence (POS) and indeed, frequently in outright prema-
ture ovarian failure (POF), also called primary ovarian
insufficiency (POI) [1]. Healthy women, delaying child-
birth for social reasons, have recently also more actively
been pursuing fertility preservation (i.e., “social fertility
preservation”), motivated by concerns about inadequate* Correspondence: ykizawa@thechr.com
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unless otherwise stated.functional ovarian reserve (FOR) by the time they will
socially be ready for conception [2,3].
A large pool of patients in need of potential fertility
preservation, the approximately 10% of women who suf-
fer from spontaneously occurring POS, have so far, how-
ever, escaped professional attention, quietly and mostly
undiagnosed progressing in their POS until becoming
clinically symptomatic at advanced stages of low func-
tional ovarian reserve (LFOR) [4]. These women in a
large majority of cases suffer from premature ovarian
aging (POA), frequently also called occult primary ovar-
ian insufficiency (OPOI), and in approximately only 1%
of cases from POF/POI. Their presenting symptom is
usually clinical infertility.
Earlier recognition of being at risk for POA/OPOI
and/or POF/POI would offer this patient population the
opportunity to preempt late diagnoses at already overtl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ing or utilizing fertility preservation techniques, would
give these young women “at risk” significant opportun-
ities at prevention of later infertility. Earlier recognition
of being “at risk” can be based on historical and clinical
(laboratory tests) risk factors.
Causes of POS are limited and predictable (Table 1).
Only the LFOR, at times associated with endometriosis,
has in the literature been proposed as a potential indica-
tion for early FOR screening [5]. Other causes of LFOR
have so far failed to attract attention. Since a large ma-
jority of women affected by POS is not recognized to
suffer from LFOR until presentation with infertility,
these women at that point often require costly infertilityTable 1 Known risk factors for premature ovarian
senescence (POA)
Medical history In association with
Conditions associated
with low numbers of
follicles at birth/menarche
Turner syndrome – associated with
POF/POI
Idiopathic/genetics – association?
Excessive recruitment FMR1 mutations
Premutation range (CGGn=55–200)
– associated with POF/POI
Monoalleleic low sub-genotype – associated
with POA/OPOI
Biallelic low sub-genotype – associated with
POA/OPOI
AMHR2 gene – associated with POF/POI
AIRE gene – associated with POF/POI
Other genetic causes BRCA1 mutations – associated with POA/
OPOI
Space occupying lesions and
Iatrogenic factors -mostly
associated with POF/POI





Other medical risk factors Endometriosis – associated with POA/OPOI
Polycystic ovarian syndrome (PCOS) –
associated with POA/OPOI
>>> > in association with low FMR1









Family history of autoimmune disease*
History of repeated pregnancy loss
Early history of maternal/
sibling menopause
*One 1st degree or two 2nd degree relatives.treatments, which with advancing female age, in addition,
decrease in effectiveness.
Age-specific follicle stimulating hormone (FSH) and/or
anti-Müllerian hormone (AMH) levels have been reported,
and allow objective determination of LFOR [4]. Serial longi-
tudinal investigations of FOR in young women “at risk,”
therefore, should already at relative young ages allow accur-
ate determinations whether patients deviate from normal
ovarian aging curves or not.
Absence of such prospective risk assessments in young
females is the principal reason why POS is currently still
only diagnosed at already advanced clinical stages.
Current understanding of POS would, however, at rela-
tively minor costs allow assessments of “risk,” and subse-
quent sequential longitudinal follow up with FOR test
parameters like AMH, until final determination whether a
patient, indeed, suffers from POS or not. Prospective FOR
screening in young “high risk” patients, could, therefore,
be viewed as the “PAP smear” for the detection of POS.
Such a diagnostic paradigm very rapidly would permit
development of accurate, and appropriately validated,
risk prediction models. Reaching similar conclusions, Cil
et al. recently made the point that policy makers should
integrate oocyte freezing into preventive paradigms for
female infertility [6].Some background on ovarian aging
Despite suggestions in the literature that ovarian stem
cells give rise to fertilizable oocytes [7], current dogma
still holds that females are born with a finite pool of fol-
licles/eggs, which rapidly depletes during intrauterine life
from a peak (~7 million follicles/oocytes), which after
birth (~1 million follicles/oocytes) continues to decline
at a somewhat slower pace through menarche (~400,000
follicles/oocytes) until menopause, when only a few hun-
dred to thousands of follicles/oocytes are left in both
ovaries [5]. (Figure 1).
With menarche, menstrual cyclicity is established, when
the ovary transforms chaotic follicle recruitment of prim-
ordial follicles into regular, usually approximately monthly
waves of developing (”growing”) follicles. A natural cycle
leads to ovulation of only a single dominant follicle/oo-
cyte. All other follicles/oocytes undergo degeneration
and apoptosis during the various stages of follicle mat-
uration, many long before the gonadotropin-sensitive
stage is reached (Figure 1).
“Ovarian age” is reflected in the total ovarian reserve
(TOR) of a patient. The largest part of TOR is made up of
still unrecruited, “resting” primordial follicles at very
primitive stages of development. “Growing” follicles are a
much smaller component of TOR, and represent the so-
called FOR. The FOR represents small follicles, which only
weeks to months later reach maturity. Ovarian stimulation
Figure 1 Declining follicle/oocyte numbers with advancing age.
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cycle, yielding multiple follicles/oocytes [5].
Genes involved in follicle recruitment appear associ-
ated with female age at menopause. Since AMH has
been suggested to play a potential role in follicle re-
cruitment, not surprisingly, one such gene controls the
AMH type II receptor (AMHR2) [8]. Produced by granu-
losa cells of small growing follicles, AMH appears to inhibit
recruitment as well as subsequent follicle growth [5,9,10].
Another gene holding back recruitment is the AIRE gene.
When mutated it leads to rapid follicle depletion and,
therefore, POF/POI (see also below) [11]. It also is closely
associated with control of immunologic self-tolerance. Mu-
tations can lead to breakdown in self-tolerance and auto-
immunity, placing this gene at crossroads of autoimmunity
and POF/POI [12].
Genes known to affect follicle recruitment, when mu-
tated, blocked or knocked out, primarily lead to rapid
depletion of primordial follicles. Genetic control of re-
cruitment, therefore, primarily appears to counteract a
natural tendency toward explosive one-time recruitment,
as still seen in more primitive water-born species.
Slow recruitment preserves follicles/oocytes at prim-
ordial stages, resulting in better TOR and FOR at later
ages. This has been demonstrated in association with
the FMR1 gene, where so-called low alleles (CGG n<26)
are associated with rapid depletion [13] and high alleles
(CGG n>34) preserve richer FOR into advanced female
ages [14].AMH as indicator of FOR
Speed of follicle recruitment has been reported to cor-
relate with number of remaining primordial follicles.
The growing follicle pool, representing FOR, therefore,
also correlates with speed of recruitment [5,9,15]. AMH
reflects this pool of small growing follicles, and is for
that reason now widely considered the best laboratory
tests to represent TOR [9,15]. Sample instability has,
however, recently led to questions about reproducibility
of results [16]. It appears that with currently commer-
cially available AMH assays, AMH maintains clinically
reasonable predictability in women with normal age-
specific FOR only up to approximately age 42. In youn-
ger women with OPOI/POA AMH is of clinical value
only as long as levels are not extremely low or high [17].
Age-specific AMH levels have been reported by vari-
ous groups, including ours [18]. Likely the most relevant
study to here proposed paradigm is the one by Kelsey
and associates, who, via literature searches and own
data, accumulated 3,260 data points, which allowed
them to define normal AMH levels in healthy premeno-
pausal women of all ages [19]. This large database also
included enough females at young ages, where fertility
centers usually lack patient populations, to permit deter-
mination of prediction limits at various confidence levels
(Figure 2).
The authors demonstrated that AMH levels rise from
birth, reaching a peak at approximately 24–25 years. From
there on, a developmental stage more familiar to fertility
Figure 2 Normal age-specific AMH ranges at various prediction limits. Modified from Kelsey et al. (16), with permission.
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fore, now permit determination of what represents normal
FOR at young ages, creating the opportunity to assess
whether a young female is in normal age-specific range of
AMH or not.
AMH, thus, now represents a tool which allows rea-
sonably accurate assessment of FOR and, therefore, in
young women, by clinical and laboratory criteria, allows
the diagnosis of likely POS (see below for definition).
This is done by assessing in young women, previously
determined as “at risk,” AMH longitudinally, and then
establishing whether they follow a normal age-specific
ovarian aging curve or not. Those who deviate from nor-
mal AMH curves into abnormally low FOR ranges can
then, with considerable reliability, at still very young ages
can be defined as, indeed, suffering from POS.Who is at risk for POS?
Since POS in all of its forms evolves insidiously as a ba-
sically asymptomatic process, OPOI/POA and POI/POF
diagnoses, as noted before, are currently mostly only
made at relatively late stages. Based on well-known risk
factors, POS is, however, to varying degrees predictable
in its occurrence (Table 1). While the statistical weight
of individual predictive risk factors remain to be deter-
mined, and likely will vary in different races, as well
demonstrated by the varying prevalence rates of low
FMR1 mutations among Caucasian, African and Asian
women, the mere presence of any one risk factor allows
for the initial designation of a young woman as “at risk”.How big the risk really is, can then be determined by the
patient’s longitudinal follow up.
The PAP smear, once again, offers a good gynecologic
analogy to the here proposed POS testing paradigm: As
in PAP smear screening risk of cytological abnormal-
ities and frequency of required screening is determined
by patient history and PAP smear results, the ultimate
risk to develop POS will be established by initial risk
determination and subsequent sequential AMH testing.
Those who deviate from AMH curves over relative
short observation periods will be identified as, indeed,
likely suffering from POS, while those following normal
aging curves can be reassured.
Table 1 summarizes risk factors for POS. Risk can be the
consequence of abnormally low follicle numbers at birth
and/or menarche, generally believed to reflect genetic ef-
fects [4]. Turner syndrome (see also below) represents a
fairly typical example, commonly characterized by prema-
ture depletion of follicles at still young ages.
POS can also be the consequence of excessive recruit-
ment. We noted before that the AMHR2 and AIRE genes
are associated with excessive recruitment. Excessive recruit-
ment has also been reported in association with low
(CGGn<26) FMR1 alleles [20]. Biallelic low FMR1 oocyte do-
nors already at very young ages demonstrate abnormally
low FOR, while monoalleleic low FMR1 donors at that
point still demonstrate normal age-specific FOR. Over a
4-year observation period, however, even monoalleleic low
FMR1 donors already deviate in AMH levels from donors
lacking low FMR1 alleles [13]. Since low FMR1 alleles are
present in approximately 25% of all U.S. women, this
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POS. An additional gene, recently associated with POA/
OPOI, is the BRCA1 gene [21].
Frequently overlooked as risk factor, are autoimmunity-
associated conditions, recently reviewed [12]. Autoimmun-
ity to thyroid often runs in parallel with autoimmunity to
ovary; in principle, however, any form of autoimmunity can
be associated with POA/OPOI or POF/POI. Since auto-
immunity is highly familial, a family history of autoimmun-
ity also represents risk towards POS, which may be why
age at menopause is highly familial [22,23]. Early maternal
and sibling ages at menopause, therefore, also should be
considered risk factors towards POS. As autoimmunity can
also be associated with repeat miscarriages [24], a history of
repeated miscarriage should also be considered a risk
factor.
Autoimmunity is believed associated at least with one-
third of POS cases [25], and has been reported in humans
in three distinct circumstances: Autoimmune (lymphocytic)
oophoritis is only rarely observed, and practically ex-
clusively only in presence of Addison’s disease [26].
Much more frequently, ovaries appear subject to a still
poorly defined autoimmune attack, associated with thyroid
autoimmunity, anti-adrenal autoimmunity and other, often
non- organ-specific, autoimmune responses [26]. The in-
creasing recognition of the X chromosome as an “auto-
immune chromosome” [27] also explains the very high
prevalence of associated autoimmunity with previously
noted Turner syndrome [28,29].
Likely, the best-defined form of autoimmune-associated
POS occurs with one of the four known autoimmune poly-
glandular syndromes (APS), so-called APS-1, also known as
the polyendocrinopathy candidiasis ectodermal dystrophy
or Whitaker syndrome. It is caused by a mutation in the
previously noted autoimmune regulator (AIRE) gene [11].
This gene is of importance in the thymus, where it regu-
lates self-tolerance from T cell attacks. Mutations in the
gene, therefore, have been associated with attacks against
“self”, i.e., autoimmunity.
A gene knockout mouse model (AIRE −/−) demonstrated
early follicle depletion, by age 20 weeks, leading in 50-60%
of animals to complete follicle depletion (POF/POI). The
AIRE gene, therefore, is the first gene established to be as-
sociated with autoimmune-induced POS [11,30].
Other medical factors, including endometriosis and
PCOS, can also suggest risk for POS. Endometriosis
can cause space-occupying lesions in ovaries, frequently
the target of surgeries, which reduce FOR. Endometri-
osis, however, is also frequently associated with auto-
immunity [31]. Similarly, PCOS can be associated with
autoimmunity [12], and with the previously noted low
FMR1 alleles, by themselves associated with POS [20].
Each in Table 1 listed risk factors, independently,
should be considered an indication for serial FORevaluations of young women until “risk” is either con-
firmed or refuted.
A prospective screening program
What differentiates here presented screening paradigm
from current practice are two crucial innovations: (i)
Identification of high-risk females at very young ages
(18–25 years); and (ii) Options for females confirmed as
“at risk” to change their pregnancy timing and/or pursue
fertility preservation.
The paradigm shift, therefore, is based on a three-step
process: (i) identification of young females at increased
risk towards POS via FMR1 screening and other risk fac-
tors (ii) confirmation or refutation of increased risk by
serial longitudinal monitoring with AMH (or other FOR
parameters); and (iii) as early counseling and interven-
tion as possible in cases where POS has been confirmed.
It is currently still unknown what percentage of young
“high risk” females in such a screening process will be
confirmed in a diagnosis of POS. Considering an ap-
proximate 10% prevalence of POS in the general popula-
tion, the number of affected females should, however, be
considerable. Multiple risk factors in one person can be
assumed to multiply overall risk, though this, too, awaits
clinical confirmation in validation studies.
Figure 3 summarizes the proposed paradigm, and pro-
poses a specific program for validation. While AMH re-
sults are generally considered steady [32], AMH levels
can also be influenced by hormonal contraceptives [32],
and do not appear as stable throughout the menstrual
cycle as initially reported [33-35]. We, therefore, recom-
mend as initial screening step two consecutive AMH
evaluations, approximately one month apart.
If a patient demonstrates AMH values in age-specific
mid-range, annual follow up testing should suffice. Timing
can be coordinated with annual gynecological examina-
tions, which, likely, can be switched to biannual testing
after 3–5 years of no observed deviations from normal
aging curves. Serial testing can, likely, be stopped the latest
after approximately 10 years of follow up if no deviations
from standard age-specific FOR curves have been ob-
served. Future validation studies should quickly determine
appropriate time intervals between tests and overall length
of required serial testing.
Low-normal age-specific AMH values at initial evalu-
ation or levels already outside of 95% confidence intervals
for age reflect a likely POS diagnosis, requiring every 3–6
months follow up testing until, with persistently low
AMH levels, a final diagnosis of POS can be reached with
certainty. Abnormally high levels, often suggest polycystic
ovary syndrome (PCOS) [9,15,16]. PCOS, in association
with low FMR1 alleles, also suggests increased risk of anti-
ovarian autoimmunity [20] and risk towards a quickly de-
pleting ovarian phenotype and subsequent POS [20,36].
Figure 3 Proposed screening paradigm.
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minority of patients, and mostly among those with auto-
immune etiology, it can proceed rapidly.Validation and cost effectiveness
As noted before, here proposed screening paradigm, of
course, requires further validation in clinical practice. Of
particular importance is the validation of individual risk
factors since they, of course, will greatly vary in their re-
spective individual impacts on risk. Because all of these
validations can only be done prospectively over time,
and will have to involve study populations of consider-
able size, they unquestionably will take time.At the same time, one, however, also has to consider
the risk of continuing to do nothing to detect POS earl-
ier in the approximately 10 percent of women who are
destined to develop POS. We would argue that the eco-
nomic cost of late diagnosis with considerable certainty
exceeds any potential screening costs, considering the
very significant costs of fertility treatments in women
POS, who in a large majority of cases, currently, are only
diagnosed at rather advanced ages. In practical terms
this means that the question to be asked is not whether
a prospective screening process to facilitate earlier diag-
nosis of POS than is currently possible is cost effective
but what the individual components of such a process
should be to make it most cost effective.
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Here presented paradigm, as of this point, suggests pro-
spective screening of selected “high-risk” females at young
ages. The Eunice Kennedy Shriver National Institute of
Child Health and Human Development (NICHD) and the
American Society for Reproductive Medicine (ASRM) re-
cently jointly held a conference “to help advance the state
of this science from theory to practice” (“Ovarian Reserve:
Regulations and Implications for Women’s Health, “San
Diego, CA, October 2012) [37]. Here proposed new treat-
ment paradigm offers, in the spirit of this conference, an
immediately implementable change to current practice.
Finally, we in a recently accepted publication also raised
the related issue of assessing risk toward POS in young
women who are planning to start utilization of hormonal
contraceptives for the long-term [38]. The rational here is
that hormonal contraceptives suppress clinical presenta-
tions of declining fertility, like cycle irregularities; but they,
in addition, affect AMH assessments [33] and, therefore
prevent reliable FOR determinations. This recommenda-
tion is based on our clinical experience with a consider-
able number of patients who, after long periods of
hormonal contraception use, suddenly found themselves
diagnosed with advanced POA/OPOI or even POF/POI.
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